根据名称进行药物检索

Zolmitriptan ODT与CAD危险因素

Zolmitriptan ODT与CAD危险因素安全配伍检测的结果。

检测结果:

Zolmitriptan ODT <> CAD危险因素

现实性: 23.07.2019 评论家: 医学副博士Shkutko P.M., in

通过权威的信息来源 Drugs.com、Rxlist.com、Webmd.com、Medscape.com，在进行所选药物与这种伴发疾病互相作用检测时，发现一些会产生负面影响或对身体危害的禁忌症及副作用。

用户:

该集团的药物，称为5-羥色胺1受体(5-HT1)激动剂，可能会导致血管痉挛性反应，包括冠状动脉血管痉挛、周围的血管缺血，结肠局部缺血。很少，严重不利的心脏活动，包括急性心肌梗塞心律失常、心脏病和死亡的已报告内的几个小时以下的行政管理5-HT1激动剂，在某些情况下甚至在病人之前没有历史或调查结果的冠状动脉疾病(計算機輔助設計)。显着升高血压力，包括高血压的危机，也已经报告了在极少数情况下，在患者和没有历史高血压，如有短暂增加血压和末稍血管抗性。在一般情况下，患者可能无法识别的計算機輔助設計作为预测的存在的风险因素(例如高血压、高胆固醇血症、吸烟、肥胖、糖尿病、强大的家族历史的加元，女性与外科手术或更年期生理或男性年龄超过40岁)不应给予5-HT1激动剂，除非心血管的评估提供了令人满意的临床证据表明缺乏計算機輔助設計、缺血性心脏病或其他重大潜在的心血管疾病。作为预防措施，制造商建议的第一剂量时可以给予下的医疗监测，在这样的病人，心电图监测被视为间隔期间立即给予帮助检测任何无症状的心脏局部缺血，可能会发生。定期的心血管评价工作应当执行期间间歇性的，长期使用。

来源

"Product Information. Axert (almotriptan)" Pharmacia and Upjohn, Kalamazoo, MI.
"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome, Research Triangle Park, NC.
MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993): 1092
Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994): 1105-6
Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996): 554-9
"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals, New York, NY.
"Product Information. Amerge (naratriptan)." Glaxo Wellcome, Research Triangle Park, NC.
"Product Information. Maxalt (rizatriptan)." Merck & Co, Inc, West Point, PA.
Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999): 704-11
Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992): 1415
Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994): 305-9
"Product Information. Frova (frovatriptan)." Endo Laboratories LLC, Chadds Ford, PA.
Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993): 861-2
Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993): 1185
Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999): 699-723
Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994): 1704-5
Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996): 329-31
Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995): 1211-3
Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992): d713-4
Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000): 275
Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996): 46-51
Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994): 622-51
"Product Information. Zomig (zolmitriptan)." Zeneca Pharmaceuticals, Wilmington, DE.